What is worth mentioning, OP‐2, along with other OP compounds, exhibited potentiated selectivity against KAT6B (as evidenced by biochemical assays), which differentiates it from other KAT6 inhibitors being investigated in the context of breast cancer. This evidence concerns the gene KAT6B and breast carcinoma.